Price$3.88-0.67 (-14.63%)
2026-04-212026-07-24
News · 26 weeks41+1200%
2026-02-012026-07-26
Mix2190d
- Insider10(48%)
- SEC Filings5(24%)
- Other4(19%)
- Earnings2(10%)
Latest news
25 items- SECSEC Form 6-K filed by PolyPid Ltd.6-K - PolyPid Ltd. (0001611842) (Filer)
- PRPolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and CanadaPolyPid to potentially receive over $320 million in upfront and milestone payments, including $30 million in upfront and near-term milestone payments, plus tiered royalties ranging from mid-teen to mid-twenties percentagesAzurity, a private global pharmaceutical company, to commercialize D-PLEX100 upon approval in the U.S. and Canada for the prevention of surgical site infections, leveraging its first-in-class commercial model. PolyPid to manufacture and supply D-PLEX100Azurity will also fund clinical development of D-PLEX100, supporting the potential label expansion in the U.S. and Canada beyond SSI indications for abdominal surgeryPartnership follows positive Phase 3 SHIELD II results, dem
- INSIDERSEC Form 4 filed by Chief Operating Officer - US Warshavsky Ori4 - PolyPid Ltd. (0001611842) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Missulawin Jonathan4 - PolyPid Ltd. (0001611842) (Issuer)
- INSIDERSEC Form 4 filed by Deputy CEO, EVP, RD, CRA Hazan Dalit Fellous4 - PolyPid Ltd. (0001611842) (Issuer)
- INSIDERSEC Form 4 filed by Director Barenholz Yechezkel4 - PolyPid Ltd. (0001611842) (Issuer)
- INSIDERSEC Form 4 filed by Director Stein Robert Benjamin4 - PolyPid Ltd. (0001611842) (Issuer)
- INSIDERSEC Form 4 filed by Director Dror-Darwish Nir4 - PolyPid Ltd. (0001611842) (Issuer)
- INSIDERSEC Form 4 filed by Director Benamram Joseph4 - PolyPid Ltd. (0001611842) (Issuer)
- INSIDERSEC Form 4 filed by Director Krinsky Itzhak4 - PolyPid Ltd. (0001611842) (Issuer)
- INSIDERSEC Form 4 filed by Director Story Brooke4 - PolyPid Ltd. (0001611842) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Akselbrad Dikla Czaczkes4 - PolyPid Ltd. (0001611842) (Issuer)
- SECSEC Form 6-K filed by PolyPid Ltd.6-K - PolyPid Ltd. (0001611842) (Filer)
- SECSEC Form 6-K filed by PolyPid Ltd.6-K - PolyPid Ltd. (0001611842) (Filer)
- SECSEC Form 6-K filed by PolyPid Ltd.6-K - PolyPid Ltd. (0001611842) (Filer)
- PRPolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀If approved, D-PLEX100 would address a critical unmet medical need in the prevention of surgical site infections PDUFA target action date currently planned for the first quarter of 2027 PETACH TIKVA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced the successful completion of its New Drug Application ("NDA") submission on a rolling review basis to the U.S. Food and Drug Administration ("FDA") for D-PLEX100, the Company's lead product candidate for the prevention of surgical site
- PRPolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor ConferencePETACH TIKVA, Israel, May 20, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that the Company's management will participate in investor meetings at the Craig-Hallum 23rd Annual Institutional Investor Conference on Thursday, May 28, 2026, at the Depot Renaissance Hotel in Minneapolis, MN. Investors interested in meeting with PolyPid should contact their Craig Hallum representative directly. About PolyPidPolyPid Ltd. (NASDAQ:PYPD) is an innovative biopharmaceutical company dedicated to elevating tre
- SECSEC Form 6-K filed by PolyPid Ltd.6-K - PolyPid Ltd. (0001611842) (Filer)
- PRPolyPid Provides Corporate Update and Reports First Quarter 2026 Financial ResultsInitiated NDA Submission to the FDA for D-PLEX₁₀₀ ; Completion Expected Imminently U.S. Commercial Partnership Discussions in Late Stages Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, May 13, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today provided a corporate update and reported financial results for the three months ended March 31, 2026. Recent Corporate Highlights: Initiated NDA Submission to the FDA under Rolling Review: On March 30, 2026, the Company initiated a New Drug Ap
- PRPolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026PETACH TIKVA, Israel, May 06, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that it will report its first quarter 2026 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, May 13, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes bef
- PRPolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual MeetingAnalysis demonstrates statistically significant reduction in the severity of surgical wound infections, with potential to lower hospital resource utilization following abdominal colorectal surgery PETACH TIKVA, Israel, April 28, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that it will present at the 45th Annual Meeting of the Surgical Infection Society, taking place on May 5-6, 2026, at the Coronado Island Marriott in Coronado, California. The presentation will focus on a detailed analysis of th
- PRPolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026PETACH TIKVA, Israel, April 13, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that the Company will present new pharmacokinetic data from the Phase 3 SHIELD II trial evaluating D-PLEX₁₀₀ at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global 2026 (formerly known as ECCMID), the world's leading congress for clinical microbiology and infectious diseases, taking place on April 17-21, 2026, in Munich, Germany. The abstract titled "Pharmacokinetics of l
- INSIDERSEC Form 3 filed by new insider Jacobovitz Yitzchak Shlomo3 - PolyPid Ltd. (0001611842) (Issuer)
- INSIDERSEC Form 3 filed by new insider Stein Robert Benjamin3 - PolyPid Ltd. (0001611842) (Issuer)
- SECSEC Form 6-K filed by PolyPid Ltd.6-K - PolyPid Ltd. (0001611842) (Filer)
PYPD FAQ
7 questionsWhat does PolyPid Ltd. do?
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product includes D-PLEX100, which is in Phase 3 clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.Where does PYPD stock trade?
PolyPid Ltd. (PYPD) is listed on NASDAQ.What sector and industry is PYPD in?
PolyPid Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did PolyPid Ltd. go public?
PolyPid Ltd. (PYPD) completed its IPO in 2020.What are analysts saying about PYPD?
PolyPid Ltd. has had 6 recent analyst actions on file. The most recent action was from Roth Capital: Buy with a $900.00 price target on 2025-06-05. Recent price targets range from $900.00 to $2400.00.What companies are similar to PYPD?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare PYPD side-by-side with any of them on Quantisnow.How can I track PYPD on Quantisnow?
Quantisnow aggregates PolyPid Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PYPD to receive live email and push alerts on every new disclosure.